iberal versus restrictive platelet transfusion for treatment of hemodynamically significant patent ductus arteriosus in thrombocytopenic preterm neonates- A randomized open label, controlled trial

Postgraduate Institute of Medical Education and Research0 个研究点目标入组 44 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1)Gestational age less than 35 weeks
•2)PDA detected for the first time at less than 14 days of postnatal age
•3)Clinically and/or echocardiographically hemodynamically significant PDA
•Note: ELBW neonates will be screened in first 48 hours as per unit policy; the rest will undergo echocardiography only when there are clinical signs of PDA.
•4)Platelet count within 24 hours prior to inclusion is less than 100,000 per microliter.
•Note: If a platelet count is already available within 24 hours prior to inclusion it will be accepted as a valid platelet count. If not, an urgent absolute platelet count will be performed.

•Echocardiographically proven structural congenital heart disease.
•2) Major life-threatening malformation
•3) Received platelet concentrate between the last available platelet count and the point of randomisation

发起方